Do Current Claims for an Alzheimer's Vaccine Properly Take Into Account the Many Defects That the Disease Causes in the Brain?
Viewpoint: Yes, current claims for an Alzheimer's vaccine properly take into account the many defects that the disease causes in the brain—the claims are based on sound experimental results regarding beta-amyloid plaques.
Viewpoint: No, a vaccine based on preventing the formation of beta-amyloid plaques is premature and could well prove ineffective—and possibly even harmful to humans.
By the end of the twentieth century, Alzheimer's disease, a condition once considered very rare, had emerged as the most common cause of dementia. Alzheimer's disease affects approximately four million people in the United States alone. Although almost half of all patients with dementia appear to suffer from Alzheimer's, the disease primarily attacks those over the age of 65. About 4% of the population over age 65 is affected; by age 80 the prevalence is about 20%. Researchers predict that, unless methods of cure or prevention are discovered very soon, the disease will afflict about 14 million Americans by 2050. Although patients in the later stages of Alzheimer's often succumb to infection, the disease itself is probably the fourth leading cause of death in the United States.
This is a free page. This page contains 201 words. This
article contains 6,120 words (approx. 20 pages at 300
words per page).
Read the rest of this Article with our Do Current Claims for an Alzheimer's Vaccine Properly Take Into Account the Many Defects That the Disease Causes in the Brain Access Pass.
